34 results on atopic dermatitis
The research question of the underlying study is: What are the effects of GMA*s on children with atopic dermatitis/ food allergy and their parents as compared with individual visits on:- physical complaints- self management- quality of life
BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) NL is part of the BIOMAP consortium, which is a EU-funded consortium through which various research projects will address three main unmet needs in AD and Pso with a broad impact on disease…
Primary Objective- To evaluate and compare the maintenance of effect of two doses of PF-04965842 (200 mg and 100 mg once daily [QD]) and placebo in subjects aged 12 and above with moderate to severe atopic dermatitis who respond to an initial open-…
The primary objective is to assess the long-term safety of nemolizumab (CD14152) in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD).The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152) in…
To investigate whether atopic dermatitis patients can be stratified based on integral analysis of clinical patient data complemented by novel biophysical measurements, in-vivo Raman spectroscopy, microbiome swabs and a oral mucosa swab (one time).
To evaluate the additional effect of coal tar treatment to a corticosteroid regimen in adults (aged >16 years of age) with moderate to severe atopic dermatitis, based on the percentage change in Eczema Area and Severity Index (EASI) at week 2…
The objective of the study is to assess the long-term safety of tacrolimus ointment 0.03% or 0.1% in the treatment of subjects with atopic dermatitis under actual use conditions, including the risk of developing cutaneous or systemic malignancies.…
Primary objective: The primary objective is to assess the efficacy and safety of nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
Primary Objective• To estimate the long term safety of 100 mg and 200 mg once daily (QD) of abrocitinib with or without topical treatments in adult and adolescent subjects who previously participated in qualifying abrocitinib atopic dermatitis (AD)…
The objective of the study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult subjects with moderate to severe AD who are candidates for systemic therapy.
The objective of the study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult subjects with moderate to severe AD who are candidates for systemic therapy.
To determine whether a potent topical CS is more effective than a mild topical CS in the treatment of children with a moderate flare-up of atopic dermatitis in primary care on short and long term.
The current study has two main objectives:- To investigate if the effectiveness of CsA differs for NMF low vs. NMF normal (corresponding with FLG mutation vs. FLG wild type) in children with moderate-to-severe AD. - To investigate if the…
Primary:To provide access to abrocitinib to adolescent and adult patients with or without background topical therapy who have inadequate treatment options due to inadequate response or intolerance to available approved medicated topical and systemic…
To evaluate efficacy of topical treatment with coal tar compared to topical treatment with corticosteroids in children aged 1 to <16 years with moderate to severe AD, based on the percentage change in Eczema Area and Severity Index (EASI) at…
To compare the MC with the UK working party diagnostic criteria (UKC) and clinical diagnosis and to refine the MC into a more convenient and reliable set of criteria.
This study compares upadacitinib to dupilumab in adolescent and adult participants with moderate to severe AD who have inadequate response to systemic therapies. Adverse events and change in the disease activity will be assessed.
The goal of this study is to assess the effectiveness of antibacterial clothing based on silver or chitosan on the doctor-reported AD severity in patients with moderate to severe AD. Secondary goals are to retrieve information about the effect of…
To evaluate the efficacy of lebrikizumab compared with placebo in patients not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16
We wish to study the absolute numbers, ratio and phenotype of CD27+IgE+ and CD27-IgE+ memory-B-cells in blood of atopic children who suffer from proven IgE-mediated asthma/hay fever, atopic dermatitis or food allergy and compare these with healthy…